Cargando…

Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial

OBJECTIVES: To study clinical predictors for radiographic progression after 1 year in an early rheumatoid arthritis (RA) trial. METHODS: In the SWEFOT trial population, disease modifying antirheumatic drug (DMARD) naïve RA patients started methotrexate; 3-month responders (DAS28 <3.2) continued (...

Descripción completa

Detalles Bibliográficos
Autores principales: Saevarsdottir, Saedis, Rezaei, Hamed, Geborek, Pierre, Petersson, Ingemar, Ernestam, Sofia, Albertsson, Kristina, Forslind, Kristina, van Vollenhoven, Ronald F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515990/
https://www.ncbi.nlm.nih.gov/pubmed/24706006
http://dx.doi.org/10.1136/annrheumdis-2013-204601
_version_ 1782382999684251648
author Saevarsdottir, Saedis
Rezaei, Hamed
Geborek, Pierre
Petersson, Ingemar
Ernestam, Sofia
Albertsson, Kristina
Forslind, Kristina
van Vollenhoven, Ronald F
author_facet Saevarsdottir, Saedis
Rezaei, Hamed
Geborek, Pierre
Petersson, Ingemar
Ernestam, Sofia
Albertsson, Kristina
Forslind, Kristina
van Vollenhoven, Ronald F
author_sort Saevarsdottir, Saedis
collection PubMed
description OBJECTIVES: To study clinical predictors for radiographic progression after 1 year in an early rheumatoid arthritis (RA) trial. METHODS: In the SWEFOT trial population, disease modifying antirheumatic drug (DMARD) naïve RA patients started methotrexate; 3-month responders (DAS28 <3.2) continued (n=147), while non-responders were randomised to addition of sulfasalazine+hydroxychloroquine (n=130) or infliximab (n=128). X-rays were scored by the Sharp-van der Hejde score (SHS) method and radiographic progression was defined as a ≥5 increase after 1 year. Potential baseline predictors of radiographic progression were tested using multivariable logistic regression, adjusted for potential confounders. RESULTS: 79 of 311 patients with available radiographs at baseline and follow-up had radiographic progression. The following baseline parameters were independent predictors of radiographic progression at 1 year: baseline erosions (adjusted OR=2.29, 95% CI 1.24 to 4.24), erythrocyte sedimentation rate (adjusted OR per tertile increase=1.72, 95% CI 1.12 to 2.65) and C-reactive protein (adjusted OR per tertile increase=1.52, 95% CI 1.03 to 2.26). Current smoking was an independent predictor of radiographic progression (adjusted OR=2.17, 95% CI 1.06 to 4.45). These results remained after further adjustment for treatment strategy. Three-dimensional matrix including current smoking status, erosions and C-reactive protein tertiles showed a 12–63% risk gradient from patients carrying none compared with all predictors. Rheumatoid factor (RF)/anti-cyclic citrullinated peptide (anti-CCP) positivity did not significantly predict radiographic progression using SHS increase ≥5 as cut-off. In a secondary exploratory analysis using cut-off >1, both RF and anti-CCP positivity were significant predictors in the unadjusted, but not the adjusted analyses. The other parameters also remained significant using this lower cut-off. CONCLUSIONS: In addition to previously described predictors, we identified smoking as a strong independent risk factor for radiographic progression in early RA. TRIAL REGISTRATION NUMBER: NCT00764725.
format Online
Article
Text
id pubmed-4515990
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-45159902015-08-03 Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial Saevarsdottir, Saedis Rezaei, Hamed Geborek, Pierre Petersson, Ingemar Ernestam, Sofia Albertsson, Kristina Forslind, Kristina van Vollenhoven, Ronald F Ann Rheum Dis Clinical and Epidemiological Research OBJECTIVES: To study clinical predictors for radiographic progression after 1 year in an early rheumatoid arthritis (RA) trial. METHODS: In the SWEFOT trial population, disease modifying antirheumatic drug (DMARD) naïve RA patients started methotrexate; 3-month responders (DAS28 <3.2) continued (n=147), while non-responders were randomised to addition of sulfasalazine+hydroxychloroquine (n=130) or infliximab (n=128). X-rays were scored by the Sharp-van der Hejde score (SHS) method and radiographic progression was defined as a ≥5 increase after 1 year. Potential baseline predictors of radiographic progression were tested using multivariable logistic regression, adjusted for potential confounders. RESULTS: 79 of 311 patients with available radiographs at baseline and follow-up had radiographic progression. The following baseline parameters were independent predictors of radiographic progression at 1 year: baseline erosions (adjusted OR=2.29, 95% CI 1.24 to 4.24), erythrocyte sedimentation rate (adjusted OR per tertile increase=1.72, 95% CI 1.12 to 2.65) and C-reactive protein (adjusted OR per tertile increase=1.52, 95% CI 1.03 to 2.26). Current smoking was an independent predictor of radiographic progression (adjusted OR=2.17, 95% CI 1.06 to 4.45). These results remained after further adjustment for treatment strategy. Three-dimensional matrix including current smoking status, erosions and C-reactive protein tertiles showed a 12–63% risk gradient from patients carrying none compared with all predictors. Rheumatoid factor (RF)/anti-cyclic citrullinated peptide (anti-CCP) positivity did not significantly predict radiographic progression using SHS increase ≥5 as cut-off. In a secondary exploratory analysis using cut-off >1, both RF and anti-CCP positivity were significant predictors in the unadjusted, but not the adjusted analyses. The other parameters also remained significant using this lower cut-off. CONCLUSIONS: In addition to previously described predictors, we identified smoking as a strong independent risk factor for radiographic progression in early RA. TRIAL REGISTRATION NUMBER: NCT00764725. BMJ Publishing Group 2015-08 2014-04-04 /pmc/articles/PMC4515990/ /pubmed/24706006 http://dx.doi.org/10.1136/annrheumdis-2013-204601 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Clinical and Epidemiological Research
Saevarsdottir, Saedis
Rezaei, Hamed
Geborek, Pierre
Petersson, Ingemar
Ernestam, Sofia
Albertsson, Kristina
Forslind, Kristina
van Vollenhoven, Ronald F
Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial
title Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial
title_full Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial
title_fullStr Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial
title_full_unstemmed Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial
title_short Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial
title_sort current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the swefot trial
topic Clinical and Epidemiological Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515990/
https://www.ncbi.nlm.nih.gov/pubmed/24706006
http://dx.doi.org/10.1136/annrheumdis-2013-204601
work_keys_str_mv AT saevarsdottirsaedis currentsmokingstatusisastrongpredictorofradiographicprogressioninearlyrheumatoidarthritisresultsfromtheswefottrial
AT rezaeihamed currentsmokingstatusisastrongpredictorofradiographicprogressioninearlyrheumatoidarthritisresultsfromtheswefottrial
AT geborekpierre currentsmokingstatusisastrongpredictorofradiographicprogressioninearlyrheumatoidarthritisresultsfromtheswefottrial
AT peterssoningemar currentsmokingstatusisastrongpredictorofradiographicprogressioninearlyrheumatoidarthritisresultsfromtheswefottrial
AT ernestamsofia currentsmokingstatusisastrongpredictorofradiographicprogressioninearlyrheumatoidarthritisresultsfromtheswefottrial
AT albertssonkristina currentsmokingstatusisastrongpredictorofradiographicprogressioninearlyrheumatoidarthritisresultsfromtheswefottrial
AT forslindkristina currentsmokingstatusisastrongpredictorofradiographicprogressioninearlyrheumatoidarthritisresultsfromtheswefottrial
AT vanvollenhovenronaldf currentsmokingstatusisastrongpredictorofradiographicprogressioninearlyrheumatoidarthritisresultsfromtheswefottrial